

CITATION REPORT

List of articles citing

Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis

DOI: 10.1080/14712598.2019.1635583

Expert Opinion on Biological Therapy, 2019, 19, 1065-1074.

Source: <https://exaly.com/paper-pdf/72094211/citation-report.pdf>

Version: 2024-04-29

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 876-881	2.3	5
3	External Evaluation of Population Pharmacokinetic Models and Bayes-Based Dosing of Infliximab. <i>Pharmaceutics</i> , 2021 , 13,	6.4	1
2	Population pharmacokinetics of intranasal dexmedetomidine in infants and young children.. <i>Anesthesiology</i> , 2022 ,	4.3	0
1	Population Pharmacokinetics of CMAB008 (an Infliximab Biosimilar) and Remicade [®] in Healthy Subjects and Patients with Moderately to Severely Active Rheumatoid Arthritis.		0